GLP-1 receptor agonists are popular weight loss drugs that help manage obesity and type 2 diabetes . There is a growing demand for GLP-1–based therapies, with research suggesting roughly 1 in 8 U.S.
adults report having ever used GLP-1 medication, with 6% currently using such drugs. Common side effects of GLP-1 drugs are those of a gastrointestinal nature, such as nausea , vomiting , diarrhea , and constipation .
Research suggests these adverse events may occur in 40 to 85% of people. Health experts advise that people can make dietary adjustments to help reduce these side effects.
Although many of these side effects are mild to moderate in severity and generally resolve shortly, adverse events remain a common cause of discontinuing the drug. While these side effects are well-documented, many people also often report anecdotal adverse events while using GLP-1 drugs.
Now, a new study published in Nature Health used AI to analyze social media posts and uncovered patient-reported side effects linked to these medications that may not yet be fully captured in clinical trials.
The analysis surfaced two potentially novel symptom categories warranting further investigation: reproductive symptoms (notably irregular menstrual cycles and unexpected bleeding) and temperature-related experiences (such as chills, hot flashes, and unusually cold sensations).
Fatigue also appeared frequently in posts, though it is less prominent in published trials.
Classic gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) were still commonly reported, consistent with what is already known.
The authors emphasize that AI-enabled parsing of lay language can illuminate patient experiences that may not be thoroughly captured in traditional trials.
Mapping colloquial symptom descriptions to standardized medical terms remains a recognized challenge, though advances in large language models are presented as enabling scalable, more consistent analysis across vast data sets.
The materials analyzed include posts referencing semaglutide and tirzepatide, drawn from Reddit communities.
The user base is described as skewed toward a mixed-gender sample with a predominance of male users on Reddit, which the authors acknowledge could influence prevalence estimates of certain symptoms.
The authors note that these signals are not prominently featured in current prescribing information, suggesting potential underrecognition in standardized safety labeling.
The interpretation highlights the possibility that women's experiences could be underrepresented if Reddit demographics limit precise rate estimation.
The authors view the Reddit-derived signals as hypothesis-generating, suggesting areas for more systematic investigation rather than definitive conclusions about causality or prevalence.
They emphasize the need for careful interpretation and corroboration with formal pharmacovigilance data and trials.
Such signals could inform clinicians and researchers about areas to monitor or inquire about in real-world practice and future studies.
While the reproductive and temperature-related signals stand out in the dataset, the exact prevalence, causality, and clinical significance remain uncertain.
The authors describe these as signals that require confirmation in prospective research and standard safety data sources.
The explicit limitation is that the study relies on self-reported online narratives, which are subject to reporting biases and lack of clinical verification where posts are concerned.